NICE National Institute for Health and Care Excellence

Putting NICE guidance into practice

Resource impact report: Implementing the NICE guidance on erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374)

Published: December 2015

This technology is commissioned by NHS England.

The guidance reviews and updates NICE technology appraisal guidance on erlotinib for the treatment of non-small-cell lung cancer and gefitinib for the second-line treatment of locally advanced or metastatic non-small-cell lung cancer.

Erlotinib is recommended as an option for treating locally advanced or metastatic non-small-cell lung cancer subject to the criteria in erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy, if the company provides erlotinib with the discount agreed in the patient access scheme.

The Department of Health and Roche Products have agreed that erlotinib will be available to the NHS with a patient access scheme which makes erlotinib available with a discount. The size of the discount is commercial in confidence. It is the responsibility of the company to communicate details of the discount to the relevant NHS organisations. Any enquiries from NHS organisations about the patient access scheme should be directed to karen.lightning-jones@roche.com.

Gefitinib is not recommended for treating locally advanced or metastatic non-small-cell lung cancer in the guidance.

It is unlikely that the guidance will result in a significant change in resource use in the NHS. The updated recommendations for erlotinib reduce the population eligible for treatment. Approximately 1800 people per year with EGFR-TK mutation-negative tumours will no longer be eligible for treatment with erlotinib under the new guidance, but will continue to be eligible for treatment with docetaxel as recommended in the

NICE guideline on diagnosis and treatment of lung cancer. It is assumed the majority of these people currently receive docetaxel. Because the price of erlotinib is commercial in confidence, NICE encourages organisations to assess the resource impact at a local level if erlotinib is currently used for treatment of people with EGFR-TK mutation-negative tumours.

This resource impact report accompanies the NICE technology guidance on erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy and should be read in conjunction with it. See terms and conditions on the NICE website.

© National Institute for Health and Care Excellence, 2015. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.